PHASE III MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF RILZABRUTINIB, ORAL BTK INHIBITOR, IN ADULTS AND ADOLESCENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA
EHA Library, David Kuter,
324406
HIBISCUS, AN ADAPTIVE, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF ORAL FT-4202, A PYRUVATE KINASE ACTIVATOR IN PATIENTS WITH SICKLE CELL DISEASE
EHA Library, Kenneth Ataga,
324435
A PHASE 2 OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY OF RUXOLITINIB ADDED TO CORTICOSTEROIDS IN PEDIATRIC SUBJECTS WITH MODERATE/SEVERE CHRONIC GVHD AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (REACH5)
EHA Library, Cristina Diaz-de-Heredia,
324451
ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON–TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
EHA Library, Kevin Kuo,
324476